Public Event Detail
Barinthus Biotherapeutics appoints Douglas Swirsky as CFO
Public historical observation from the Merrowstone archive. This page shows event-level context only. Accepted assertions, evidence lineage, and relationship intelligence remain part of the premium research layer.
Event summary
Barinthus Biotherapeutics has announced the appointment of Douglas Swirsky as Chief Financial Officer and principal accounting officer, effective May 1, 2026. Swirsky will provide his services through Grand Strand BioAdvisors LLC, receiving a monthly fee as part of an arrangement to strengthen the company's financial leadership. Barinthus (BRNS) currently holds a Buy rating from analysts with a $7.00 price target, though TipRanks’ AI Analyst, Spark, rates it as Neutral due to weak financial performance and bearish technicals.